newsfilter
← Latest News
GlobeNewswire·

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the